Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM512 in Chronic Spontaneous Urticaria
NCT07166211Phase 2Recruiting
- Sponsor
- Keymed Biosciences
- Start
- Nov 2025
- Primary completion
- Nov 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CM512 in chronic spontaneous urticaria (CSU) (2 arms), sponsored by Keymed Biosciences. Primary endpoint: 7-day Urticaria Activity Score at 16 weeks. Started Nov 2025; status: recruiting.
02
Drugs
CM512
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT07166211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07166211.